Amendments to the Claims:

1. (canceled)

2. (currently amended) A process as claimed in ~~claim 1~~ claim 8, wherein the molar ratio between active ingredient and cyclodextrin is in the range from 0.1 to 4.0.

3. (currently amended) A process as claimed in ~~claim 1~~ claim 8, wherein the plastic mixture is shaped in a molding calendar to produce the dosage forms.

4. (previously presented) A process as claimed in claim 3, wherein a molding calendar with counterrotating molding rolls is used, with at least one of the molding rolls having on its surface depressions to receive and shape the plastic mixture.

5. (currently amended) A solid dosage form which is essentially free of aliphatic C_2-C_8-di- and -tricarboxylic acids and aromatic C_6-C_{10}-monocarboxylic acids, obtainable by a process as claimed in ~~claim 1~~ claim 8.

6. (currently amended) A solid dosage form as claimed in claim 5, wherein at least 10% by weight of the active ingredient ~~are~~ is present in the form of a cyclodextrin/active ingredient complex.

7. (previously presented) The solid dosage form of claim 5, said dosage form having release rate of active ingredient of at least 18% after 20 minutes, determined by the USP paddle method (0.1M hydrochloric acid; pH 1.0; 150 rpm).

8. (currently amended) ~~The process of claim 1, wherein~~ A process for producing solid dosage forms comprising:

mixing and plasticizing

a) 0.5 to 25% by weight of the at least one active ingredient,

b) 0.5 to 60% by weight of the at least one cyclodextrin,

c) 50 to 98% by weight of the at least one polymeric binder, and

e) 0 to 50% by weight of ~~conventional~~ excipients,

~~are mixed and plasticized~~ at a temperature below 170°C without adding a solvent, and shaping the resulting plastic mixture ~~is shaped~~ to produce the solid dosage form.

9. (new) The method of claim 8 further comprising

premixing said at least one polymeric binder and at least one cyclodextrin,

converting said at least one polymeric binder and at least one cyclodextrin into a plastic state, and

mixing said at least one active ingredient with said plastic state.

10. (new) The method of claim 9 further comprising:

premixing said excipient with said at least one polymeric binder and at least one cyclodextrin.

11. (new) A solid dosage form that is essentially free of aliphatic C_2-C_8-di-and -tricarboxylic acid and aromatic C_6-C_{10}-monocarboxylic acid.

12. (new) The dosage form of claim 11, which comprises:
0.5 to 25% by weight of the at least one active ingredient,
0.5 to 60% by weight of the at least one cyclodextrin,
50 to 98% by weight of the at least one polymeric binder, and
0 to 50% by weight of excipient.

13. (new) The dosage form of claim 11, wherein said active ingredient is a vitamin, a mineral

extract, a plant extract, a plant preparation with pharmaceutically active constituent, a plant treatment agent, an insecticide, a therapeutic peptide, a vaccine or a combination thereof.

14. (new) The dosage form of claim 11, wherein said at least one cyclodextrin is α-1,4-glycosidically linked glucose unit.

15. (new) The dosage form of claim 11, wherein said at least one cyclodextrin is a reaction product of the reaction of a cyclodextrin with a compound selected from the group consisting of alkylene oxide, alkyl halide, acid chloride, epihalohydrin, isocyanate, halogenated carboxylic acid and combinations thereof.

16. (new) The dosage form of claim 11, wherein said at least one polymeric binder is natural.

17. (new) The dosage form of claim 11, wherein said at least one polymeric binder is synthetic.

18. (new) The dosage form of claim 11, wherein said at least one polymeric binder is at least partly soluble in a physiological medium.